InterMune Cut to Market Perform at Wells Fargo & Co. (ITMN)
InterMune (NASDAQ:ITMN) was downgraded by stock analysts at Wells Fargo & Co. from an “outperform” rating to a “market perform” rating in a report issued on Thursday, TheFlyOnTheWall.com reports. The analysts noted that the move was a valuation call.
In other InterMune news, EVP Paul D. Arata sold 7,500 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $50.00, for a total transaction of $375,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs downgraded shares of InterMune from a “buy” rating to a “neutral” rating in a research note on Thursday, August 14th. They now have a $49.00 price target on the stock, down previously from $52.06. They noted that the move was a valuation call. Separately, analysts at William Blair raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Friday, August 8th. Finally, analysts at Stifel Nicolaus raised their price target on shares of InterMune from $51.00 to $53.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $45.33.
InterMune (NASDAQ:ITMN) traded down 1.46% during mid-day trading on Thursday, hitting $53.31. 1,088,488 shares of the company’s stock traded hands. InterMune has a 1-year low of $10.95 and a 1-year high of $55.24. The stock has a 50-day moving average of $45.3 and a 200-day moving average of $35.71. The company’s market cap is $5.756 billion.
InterMune (NASDAQ:ITMN) last announced its earnings results on Wednesday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The company’s quarterly revenue was up 141.2% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.73 earnings per share for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Receive News & Ratings for InterMune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterMune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.